Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 1, 2025

LoVo

RRID:CVCL_0399
Type: Cell Line

Proper Citation

(RRID:CVCL_0399)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0399

Proper Citation: (RRID:CVCL_0399)

Sex: Male

Defining Citation: PMID:1260746, PMID:3335022, PMID:7104989, PMID:7651727, PMID:8197130, PMID:8464898, PMID:9000147, PMID:9000572, PMID:9290701, PMID:9294210, PMID:9515795, PMID:9715273, PMID:10612807, PMID:10674020, PMID:10737795, PMID:11226274, PMID:11314036, PMID:11414198, PMID:11416159, PMID:11526487, PMID:11668190, PMID:12068308, PMID:12584437, PMID:12615714, PMID:12661003, PMID:15771911, PMID:15900046, PMID:16418264, PMID:16854228, PMID:18258742, PMID:19927377, PMID:19941903, PMID:20164919, PMID:20570890, PMID:20606684, PMID:20831567, PMID:22460905, PMID:24042735, PMID:24755471, PMID:25485619, PMID:25877200, PMID:25926053, PMID:25944804, PMID:25984343, PMID:26537799, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28683746, PMID:28854368, PMID:29101300, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:32172478, PMID:34320349, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: LoVo

Synonyms: LOVO

Cross References: BTO:BTO_0000666, CLO:CLO_0007377, CLO:CLO_0007378, CLO:CLO_0050632, EFO:EFO_0006639, MCCL:MCC:0000293, CLDB:cl3248, CLDB:cl3249, CLDB:cl3250, CLDB:cl4981, AddexBio:C0009011/380, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-229, BCRC:60148, BCRJ:0332, BioGRID_ORCS_Cell_line:405, BioSample:SAMN03470964, BioSample:SAMN03471476, BioSample:SAMN03472104, BioSample:SAMN03472362, BioSample:SAMN03473360, BioSample:SAMN05292432, BioSample:SAMN10988310, cancercelllines:CVCL_0399, CCLV:CCLV-RIE 1151, CCRID:1101HUM-PUMC000164, CCRID:3101HUMSCSP514, CCRID:3101HUMTCHu82, CCRID:4201HUM-CCTCC00646, CCTCC:GDC0186, Cell_Model_Passport:SIDM00839, ChEMBL-Cells:CHEMBL3307691, ChEMBL-Targets:CHEMBL614721, CLS:300266, ColonAtlas:LOVO, Cosmic:711256, Cosmic:720330, Cosmic:724842, Cosmic:738931, Cosmic:873702, Cosmic:876724, Cosmic:887220, Cosmic:889534, Cosmic:897741, Cosmic:905003, Cosmic:907790, Cosmic:913886, Cosmic:948858, Cosmic:985997, Cosmic:995396, Cosmic:1043567, Cosmic:1057754, Cosmic:1066209, Cosmic:1122327, Cosmic:1132566, Cosmic:1132691, Cosmic:1184084, Cosmic:1184329, Cosmic:1187308, Cosmic:1223145, Cosmic:1312303, Cosmic:1466817, Cosmic:1479597, Cosmic:1482522, Cosmic:1486133, Cosmic:1524331, Cosmic:1552182, Cosmic:1571770, Cosmic:1676729, Cosmic:1609489, Cosmic:1708412, Cosmic:1803948, Cosmic:1927244, Cosmic:1945867, Cosmic:1995488, Cosmic:2267319, Cosmic:2301996, Cosmic:2389574, Cosmic:2588707, Cosmic:2646767, Cosmic:2651865, Cosmic:2664049, Cosmic:2667975, Cosmic:2760062, Cosmic:2787548, Cosmic:2800576, Cosmic-CLP:907790, DepMap:ACH-000950, DSMZ:ACC-350, DSMZCellDive:ACC-350, ECACC:87060101, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS024NHD, ENCODE:ENCBS080BPN, GDSC:907790, GEO:GSM206517, GEO:GSM274719, GEO:GSM274720, GEO:GSM274729, GEO:GSM513820, GEO:GSM514296, GEO:GSM741268, GEO:GSM784014, GEO:GSM887274, GEO:GSM888349, GEO:GSM1346882, GEO:GSM1374627, GEO:GSM1374628, GEO:GSM1374629, GEO:GSM1374630, GEO:GSM1448163, GEO:GSM1670055, GEO:GSM2550007,

GEO:GSM3591765, IARC_TP53:21485, ICLC:HTL99028, IZSLER:BS TCL 205, JCRB:IFO50067, JCRB:JCRB9083, KCB:KCB 200718YJ, KCLB:10229, LiGeA:CCLE_421, LINCS_LDP:LCL-1181, Lonza:1021, MetaboLights:MTBLS227, NCI-DTP:LOVO, PharmacoDB:LoVo_856_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_0399, PubChem_Cell_line:CVCL_0399, RCB:RCB1639, SKY/M-FISH/CGH:2878, TKG:TKG 0344, Ubigene:YC-C137, Wikidata:Q54902894

ID: CVCL_0399

Record Creation Time: 20250131T201239+0000

Record Last Update: 20250131T202816+0000

Ratings and Alerts

No rating or validation information has been found for LoVo.

Warning: Discontinued: TKG; TKG 0344
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 691 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kim E, et al. (2025) Diet therapy abates mutant APC and KRas effects by reshaping plasma membrane cholesterol nanodomains. Biophysical journal, 124(3), 508.

Shin Y, et al. (2024) MMP-9-dependent proteolysis of the histone H3 N-terminal tail: a critical epigenetic step in driving oncogenic transcription and colon tumorigenesis. Molecular oncology, 18(8), 2001.

Li HM, et al. (2024) PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway. The FEBS journal.

Tokiwa T, et al. (2024) Chlorogenic acid suppresses the expression of matrix metalloproteinase-7 and cell invasiveness to almost the same extent as isofraxidin in human colorectal cancer cells. In vitro cellular & developmental biology. Animal.

Jochems F, et al. (2024) Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. Cell death and differentiation.

Iwata M, et al. (2024) Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. Journal of cellular and molecular medicine, 28(7), e18193.

Wang R, et al. (2024) EEF1D stabilized by SRSF9 promotes colorectal cancer via enhancing the proliferation and metastasis. International journal of cancer, 155(8), 1487.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Jacob J, et al. (2024) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer. bioRxiv : the preprint server for biology.

Wu Z, et al. (2024) PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial. Med (New York, N.Y.), 5(8), 998.

Liu Y, et al. (2024) Translocational attenuation mediated by the PERK-SRP14 axis is a protective mechanism of unfolded protein response. Cell reports, 43(7), 114402.

Lee CJ, et al. (2024) The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. Nature communications, 15(1), 10422.

Chen D, et al. (2024) RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis. Cancer research, 84(17), 2856.

Chen HC, et al. (2024) Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO molecular medicine, 16(9), 2233.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell

chemical biology, 31(7), 1247.

Liu G, et al. (2024) Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer. Oncology research, 32(3), 585.

Savage SR, et al. (2024) Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell, 187(16), 4389.

Zhu X, et al. (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. Cancer research, 84(1), 84.

Zhu X, et al. (2024) The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer. Journal of experimental & clinical cancer research : CR, 43(1), 7.

Grze? M, et al. (2024) A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer. Cell death & disease, 15(8), 638.